Initiate clinical testing for novel RASP modulators
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 29 Mar 2022
- Due
- 31 Dec 2023
- Checked
- 2 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Novel RASP Modulators for Systemic and Retinal Disease Expected to Initiate Clinical Testing in 2023”
What we found
Evidence strength A What the grades mean
The company did not initiate clinical testing for the novel RASP modulators ADX-246 and ADX-248 in 2023 as originally expected, pushing the initiation of these trials to 2024 and later.
-
A Aldeyra Therapeutics, Inc. 10-K filed 2024-03-07
“Clinical trials of the RASP modulators ADX‑246 in systemic immune-mediated disease and ADX‑248 in retinal disease are expected to be initiated in 2024” ✓ confirmed on the page
Market reaction: the shares moved -17.6% against the S&P 500 over the three sessions around the disclosure (6 Mar 2024 to 11 Mar 2024). What this measures
Checked 2 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Product other
- Indicative materiality
- Low rules
- Action
- Initiate
- Deliverable
- Clinical testing for novel RASP modulators
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Aldeyra Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-ALDX-003456 · Corrections policy